Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3690

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others], Infection Type [Superficial Antifungal Infection and Systemic Antifungal Infection], Dosage form [Drugs, Ointment, Powder, and Others] and Therapeutic Indication [Aspergillosis, Dermatophytosis, Candidiasis, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_172370
Pages: 190
Jun 2017 | 2601 Views
face gplus_n
Author's : Garima Chandra & Divya Srivastava
Tables: 80
Charts: 61
twit_n pr_n

Antifungal Drugs Market Overview:

Global Antifungal Drugs Market is expected to rise from $13,719 million in 2016 to $17,718 million by 2023. The industry is anticipated to register a CAGR of 3.7%, during the forecast period, 2017 - 2023. The antifungal drugs detect and eliminate fungal pathogens providing minimal side effect to the body. The fungal infection in the body is caused due to unhygienic and unclean environments wherein fungal agent thrive. These agents multiply by spreading spores that subsequently lead to infection on skin (superficial) or when inhaled (systemic)-fungal infections. The fungal infection leads to candidiasis, fungal pneumonia, mucormycosis, and other diseases. These infections are mostly non-lethal, but can result in death in rare cases.

Continuous focus of key players towards the development of new generic as well as innovative anti-infective drugs and formulation technologies to combat serious fungal infections drive the antifungal drugs market. This is evident from the various launches made by many major players. For instance, Basilea Pharmaceutica Ltd. launched CRESEMBA (isavuconazole) in UK, in 2016. This is a new azole antifungal drug prescribed for treatment of mucormycosis.

The global antifungal drugs market is segmented based on drug type, therapeutic indications, dosage forms, infection type, and geography. Based on drug type, it is classified into echinocandins, azoles, polyenes, allylamines, and other drugs. Furthermore, based on therapeutic indications the market is categorized into aspergillosis, dermatophytosis, candidiasis, and others. In terms of dosage forms, it is divided into powders, ointments, drugs, and pastes. Based on infection type, the market is bifurcated into superficial and systemic antifungals. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Among the drug type, azole occupied three-eighths of the total market share in 2016. This is the highest amongst all, and is expected to maintain this trend during the forecast period. The trend is noticed due to rise in awareness about drug availability and fungal infections, globally. In the indication type, the dermatophytosis is expected to grow at the highest CAGR of 4.1% during the forecast period.

Global Antifungal Drugs Market Segmentation

Global Antifungal Drugs Market Segmentation

Get more information on this report : Request Sample Pages

Drivers, Restraints, and Opportunities

Factors that accelerate  demand for the antifungal drugs market are growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad fungal infections, and increase in demand for the drugs to combat the related diseases. However, presence of counterfeit drugs and resistance toward antifungal drugs restrict the market growth. In addition, increase in R&D expenditure coupled with funding from the public & private sector is expected to provide lucrative growth opportunities to the industry.

Impact Analysis: Drivers & Restraints

Antifungal Drugs Market Segmentation Impact Analysis: Drivers & Restraints

Get more information on this report : Request Sample Pages

India Antifungal Drugs Market

The rise in awareness toward personal care drives the antifungal drugs market growth in India. In addition, India provides a tropical environment for breeding of diverse types of fungi, and therefore provides a lot of opportunities to the pharmaceutical vendors to keep the drug market flooded with various anti-fungal drugs. Hence, the antifungal drugs market is expected to flourish in the near future in India.

India Antifungal Drugs Market

Get more information on this report : Request Sample Pages

The report provides a comprehensive analysis of the key players operating in the global antifungal drugs market, such as Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc.

The other players of the global antifungals drugs market include Astellas Pharma, Inc., Sigma-Aldrich Corporation, Agilent Technologies, Inc., Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Kramer Laboratories, Basilea Pharmaceutical Ltd., Valeant Pharmaceuticals International, Inc., and Tecan Group.

Key Benefits of the Antifungal Drugs Market Report:

  • It provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
  • It offers discussion to enable the stakeholders to capitalize on the prevailing market opportunities
  • It profiles key market players and their strategies which help to understand the competitive outlook of the market
  • It incorporates the Porters Five Forces model to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players

Antifungal Drugs Market Key Segments:

By Drug Type

  • Echinocandins
    • Caspofungin
    • Micafungin
    • Anidulafungin
    • Others
  • Azoles
    • Imidazoles
    • Voricanazole
    • Thiazoles
    • Others
  • Polyenes
    • Amphotericin B
    • Candicidin
    • Hamycin
    • Natamycin
    • Others
  • Allylamines
    • Butenafine
    • Terbinafine
    • Naftifine
    • Others

By Infection Type

  • Superficial Antifungal Infections
  • Systemic Antifungal Infections

By Therapeutic Indications

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Dosage Forms

  • Powders
  • Ointments
  • Drugs
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Egypt
    • Israel
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases

3.6.2. Restraints

3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs

3.6.3. Opportunities

3.6.3.1. Patent expirations and increasing funding from public & private organizations

Chapter: 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SUPERFICIAL ANTIFUNGAL INFECTION

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SYSTEMIC ANTIFUNGAL INFECTION

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ECHINOCANDINS

5.2.1. Market size and forecast
5.2.2. Micafungin

5.2.2.1. Market size and forecast

5.2.3. Caspofungin

5.2.3.1. Market size and forecast

5.2.4. Anidulafungin

5.2.4.1. Market size and forecast

5.2.5. Others

5.2.5.1. Market size and forecast

5.3. AZOLES

5.3.1. Market size and forecast
5.3.1. Imidazoles

5.3.1.1. Market size and forecast

5.3.2. Voricanazole

5.3.2.1. Market size and forecast

5.3.3. Thiazoles

5.3.3.1. Market size and forecast

5.3.4. Others

5.3.4.1. Market size and forecast

5.4. POLYENES

5.4.1. Market size and forecast
5.4.2. Amphotericin B

5.4.2.1. Market size and forecast

5.4.3. Candicidin

5.4.3.1. Market size and forecast

5.4.4. Hamycin

5.4.4.1. Market size and forecast

5.4.5. Natamycin

5.4.5.1. Market size and forecast

5.4.6. Others

5.4.6.1. Market size and forecast

5.5. ALLYLAMINES

5.5.1. Market size and forecast
5.5.1. Terbinafine

5.5.1.1. Market size and forecast

5.5.2. Butenafine

5.5.2.1. Market size and forecast

5.5.3. Naftifine

5.5.3.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

Chapter: 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ASPERGILLOSIS

6.2.1. Market size and forecast

6.3. DERMATOPHYTOSIS

6.3.1. Market size and forecast

6.4. CANDIDIASIS

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

Chapter: 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. POWDER

7.2.1. Market size and forecast

7.3. OINTMENTS

7.3.1. Market size and forecast

7.4. DRUGS

7.4.1. Market size and forecast

7.5. OTHERS

7.5.1. Market size and forecast

Chapter: 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

Chapter: 9 COMPANY PROFILES

9.1. PFIZER INC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. SANOFI S.A

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. GILEAD SCIENCES INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. MERCK & CO., INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. NOVARTIS INTERNATIONAL AG

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. ABBOTT LABORATORIES

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. BAYER AG

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. SCYNEXIS INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. ENZON PHARMACEUTICALS INC.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. GLAXOSMITHKLINE PLC

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL SUPERFICIAL ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL SYSTEMIC ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR MICAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR CASPOFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR ANIDULAFUNGIN, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR IMIDAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR VORICANAZOLE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR THIAZOLES, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR AMPHOTERICIN B, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR CANDICIDIN, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR HAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR NATAMYCIN, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 24. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 25. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR TERBINAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 27. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR BUTENAFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 28. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR NAFTIFINE, BY REGION, 2016-2023 ($MILLION)
TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2016-2023 ($MILLION)
TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ASPERGILLOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET FOR DERMATOPHYTOSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET FOR CANDIDIASIS, BY REGION, 2016-2023 ($MILLION)
TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET FOR THERAPEUTIC INDICATIONS BY REGION, 2016-2023 ($MILLION)
TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POWDER, BY REGION, 2016-2023 ($MILLION)
TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OINTMENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 38. GLOBAL ANTIFUNGAL DRUS MARKET FOR DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER DOSAGE FORMS, BY REGION, 2016-2023 ($MILLION)
TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 43. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 44. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 45. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 46. EUROPE ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 47. EUROPE ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 48. EUROPE ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 49. EUROPE ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 50. EUROPE ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 52. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 53. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 55. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. LAMEA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
TABLE 58. LAMEA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 59. LAMEA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
TABLE 61. PFIZER: COMPANY SNAPSHOT
TABLE 62. PFIZER: OPERATING SEGMENTS
TABLE 63. SANOFI: COMPANY SNAPSHOT
TABLE 64. SANOFI: OPERATING SEGMENTS
TABLE 65. GILEAD: COMPANY SNAPSHOT
TABLE 66. GILEAD: OPERATING SEGMENTS
TABLE 67. MERCK: COMPANY SNAPSHOT
TABLE 68. MERCK: OPERATING SEGMENTS
TABLE 69. NOVARTIS: COMPANY SNAPSHOT
TABLE 70. NOVARTIS: OPERATING SEGMENTS
TABLE 71. ABBOTT: COMPANY SNAPSHOT
TABLE 72. ABBOTT: OPERATING SEGMENTS
TABLE 73. BAYER: COMPANY SNAPSHOT
TABLE 74. BAYER: OPERATING SEGMENTS
TABLE 75. SCYNEXIS: COMPANY SNAPSHOT
TABLE 76. SCYNEXIS: OPERATING SEGMENTS
TABLE 77. ENZON: COMPANY SNAPSHOT
TABLE 78. ENZON: OPERATING SEGMENTS
TABLE 79. GSK: COMPANY SNAPSHOT
TABLE 80. GSK: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF ANTIFUNGAL DRUGS MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL ANTIFUNGAL DRUGS MARKET
FIGURE 13. U.S. ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. AUSTRALIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 32. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SANOFI: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. GILEAD: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. GILEAD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. GILEAD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. NOVARTIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. BAYER: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. BAYER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. SCYNEXIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. SCYNEXIS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. SCYNEXIS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. ENZON: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. ENZON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. ENZON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. GSK: REVENUE BY GEOGRAPHY, 2016 (%)

 

Since the past decades, the improved diagnostics and availability of new antifungals have revolutionized the field of medical mycology. Moreover, the continuous R&D in the vaccines and antibody-based immunotherapy provides a steady growth to the pharmaceutical sector. In addition, high prevalence of fungal infection accelerates the growth of the antifungal drugs market. In this regard, many key players develop novel antifungal therapeutics that provide relief from varied antifungal infections.

Dermal infections occur in high number and hence with advertisements and endorsements many pharmaceutical companies develop several OTC drugs in the market for the treatment of dermal infections. These drugs are cost-effective and are available in various forms, such as powders, creams, solutions, and others. Since, the topical antifungal drugs such as butenafine, clotrimazole, nitrate, hydrochloride, tolnaftate, and terbinafine are effective in the treatment of fungal skin infections, the coming years are expected to witness an exponential increase in the demand for antifungal medicines. The recent development of novel antifungal agents has significantly contributed to the treatment of fungal disease successfully. Many antifungal drugs were outdated or of obsolete technology and patents were expired. However, increase in need for new, highly effective, and superior resistance anti-fungal technologies is the key factor to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Antifungal Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3690
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4099
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $4999
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6004
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8373
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo